

a 2005 0046

The invention refers to medicine, in particular to obstetrics and gynecology and may be used for the interruption of the early pregnancy, namely up to 56 days, associated with amenorrhea.

Summary of the invention consists in that it is administered *per os* 200 mg of mifepriston, then after the expiry of 24...48 hours it is administered fourfold intravaginally, every 6 hours, for one suppository, containing 50 mg of S-ethyl isothiourone bromide (isoturone).

Claims: 1